Loss narrows at EpiCept in 2Q
EpiCept Corp., a biotech company based in Tarrytown, reported a net loss of $7.1 million, or 6 cents a share, during the second quarter, compared to a net loss of $7.8 million, or 15 cents a share, a year earlier. Revenues of $91,000 rose from $42,000 a year earlier.
“During the second quarter we continued to advance our important product candidates both commercially and in the clinic,” Chief Executive Officer Jack Talley said.
One of the company’s products is Ceplene, which was approved in the European Union for treatment of patients with Acute Myeloid Leukemia.